Navion Neurosciences Inc.
StreetZero Signal 61
About Navion Neurosciences Inc.
Navion Neurosciences, Inc. is a preclinical-stage biotechnology company developing precision sodium-channel medicines for neurological diseases such as epilepsy and neuropathic pain. Through its NaViGATion™ platform, the company integrates AI-enabled chemistry, structural biology, human disease biology, and ion-channel expertise to discover differentiated therapeutics for diseases of neuronal hyperexcitability. It is headquartered at the Commonwealth Bio Accelerator in Charlottesville, Virginia.
LATEST FUNDINGSeed
$1.9M
Announced 2026-09-22
TOTAL RAISED$20.495M
IN THE NEWS
- 🔗 Navion Neurosciences Funding & Company Profile | The Venture Codex
- 🔗 Navion Neurosciences company information, funding & investors | Dealroom.co
- 🔗 Navion Neurosciences Closes $10.8 Million Seed Financing to Advance Precision Sodium-Channel Medicines for Epilepsy and Neuropathic Pain - Lumira Ventures | Venture Capital Life Sciences | Canada
- 🔗 Charlottesville's Navion Neurosciences Raises $10.8 Million to Build Precision Medicines for Misfiring Neurons | BioBuzz
- 🔗 Navion Neurosciences -
EMPLOYEES—
FOUNDED—
HQCharlottesville, VA, United States
Industry
Other Health Care
Tags
BiotechNeuroscienceSeedPrecision Medicine
Investors
Key highlights
- Closed $10.8M Seed round in September 2026 led by Angelini Lumira Biosciences Fund.
- Developing precision sodium-channel therapeutics via the NaViGATion AI-enabled platform.
- Headquartered at Commonwealth Bio Accelerator in Charlottesville, Virginia.
- Targets epilepsy and neuropathic pain through modulation of neuronal hyperexcitability.
Ask StreetZero about Navion Neurosciences Inc.
Put our AI to work on this deal.
Similar companies
Other Other Health Care deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account